Effects of myo-inositol plus folic acid on ovarian morphology and oocyte quality in PCOS mouse model

• Published in: Zygote (Cambridge) 2023-04, Vol.31 (2), p.111-122
• Main Authors: Haghighi, Maryam, Mehdizadeh, Mehdi, Amjadi, Fatemehsadat, Zandieh, Zahra, Najafi, Mohammad, Artimani, Tayebe, Mohammadi, Fatemeh, Mehdizadeh, Rana
• Format: Article
• Language: English
• Subjects: Acids; Adenosine Triphosphate - pharmacology; Androgens; Animals; Apoptosis; ATP; Corpus luteum; Dehydroepiandrosterone; Dehydroepiandrosterone - pharmacology; Diameters; Dosimetry; Ethical standards; Evaluation; Female; Fluorimetry; Fluorometry; Folic acid; Folic Acid - pharmacology; Follicles; Gametocytes; Glutathione; Histopathology; Humans; Infertility; Inositol; Inositol - pharmacology; Inositols; Insulin resistance; Leukocytes; Metabolism; Mice; Morphology; Oocytes; Ovaries; Ovulation; Oxidative stress; Polycystic Ovary Syndrome; Reactive Oxygen Species; Testosterone; Testosterone - pharmacology; Theca; Thickness ratio; Vagina; Vitamin B
• ISSN: 0967-1994; 1469-8730
• DOI: 10.1017/S0967199422000557

Although the role of myo-inositol (MYO) in promoting the oocyte quality of PCOS patients has been documented in human studies; the cellular effects of this supplement on oocytes have not been directly examined due to ethical limitations. In the first phase of this study, MYO dosimetry was carried out simultaneously with the PCOS model development. An effective dose was obtained following the assessment of fasting insulin and testosterone levels using ELISA and ovarian morphology appraisal by histopathology. In the second phase, following the continuous administration of the effective dose of MYO and dehydroepiandrosterone (DHEA), cellular evaluation was performed. The quality of oocytes from superovulation was analyzed by examining maturity and normal morphology percentage using a stereomicroscope, intracellular reactive oxygen species (ROS) and glutathione (GSH) levels using fluorometry, and ATP count evaluation using ELISA. The results revealed that, among the four different MYO concentrations, the 0.36 mg/g dose compared with the DHEA group reduced testosterone levels and large atretic antral follicles (LAtAnF) diameter. This dose also increased the corpus luteum count and the granulosa:theca (G/T)layer thickness ratio in antral follicles. Furthermore, this dose increased mature oocytes and normal morphology percentage, ATP count, and GSH levels; however, it decreased ROS levels in mature oocytes. Our findings provide the grounds for further cellular and molecular studies on the PCOS mouse model, suggesting that the improvement in mitochondrial function and its antioxidant properties is probably one of the mechanisms by which MYO increases oocyte quality.